Anika Therapeutics (ANIK)

• Market cap: $132M
• 1 day: 0.44%
• 5 days: 7.25%
• 1 month: -19.06%
• 3 months: -17.68%
• 6 months: -48.16%
• Year to date: -43.43%
• 1 year: -63.78%
• 5 years: -75.11%
• 10 years: -73.24%
• Sector: Healthcare
• Industry: Drug Manufacturers - Specialty & Generic

About: Anika Therapeutics Inc is an orthopedic medicines company. It is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies. The company focuses on orthopedics, including osteoarthritis pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies. Geographically, it derives a majority of its revenue from the United States and also has its presence in Europe and Other countries.

Employees: 288

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

19% more repeat investments, than reductions

Existing positions increased: 38 | Existing positions reduced: 32

1.07% less ownership

Funds ownership: 89.41% [Q1] → 88.34% (-1.07%) [Q2]

6% less funds holding

Funds holding: 108 [Q1] → 101 (-7) [Q2]

29% less first-time investments, than exits

New positions opened: 15 | Existing positions closed: 21

30% less capital invested

Capital invested by funds: $191M [Q1] → $134M (-$56.7M) [Q2]

50% less call options, than puts

Call options by funds: $2K | Put options by funds: $4K

67% less funds holding in top 10

Funds holding in top 10: 3 [Q1] → 1 (-2) [Q2]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $15 64% upside
• Avg. target: $15 64% upside
• High target: $15 64% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

Barrington Research Michael Petusky

64% upside $15

Outperform Maintained

31 Jul 2025